Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytokine-induced memory-like natural killer cells
- Development stage
- Phase 2
- Lead developer
- Cincinnati Children's Hospital Medical Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Cytokine-induced memory-like natural killer cells are a specialized type of immune cell therapy created by briefly exposing natural killer (NK) cells to a combination of cytokines (typically interleukin (IL)-12, IL-15, and IL-18[1][2]). After this brief stimulation and a subsequent resting period, these cells demonstrate enhanced effector functions, including increased cytokine production and cytotoxicity against tumor targets[3]. This "memory-like" property allows them to maintain their enhanced functionality for weeks following the initial activation[2][5]. Unlike conventional NK cells, CIML NK cells exhibit adaptive and memory-like features despite being classified as innate lymphoid cells[2]. They undergo transcriptional, epigenetic, and metabolic reprogramming that contributes to their enhanced capabilities[2].
- Other names
- CIML NKmemory-like NK cellsmlNK
02
Targets
NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on cytokine-induced memory-like natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytokine-induced memory-like natural killer cells.